Thermo Fisher Scientific Inc. has released its 2025 Form 10-K report, highlighting a 4% increase in total revenues to $44,556 million and a 7% rise in diluted EPS to $17.74. The report details robust performance across its four key business segments, strategic acquisitions to enhance proteomics and bioproduction capabilities, and ongoing investments in innovation and global expansion. The company also addresses challenges and risks including market competition, economic volatility, and regulatory pressures.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
THERMO FISHER SCIENTIFIC INC. SEC 10-K Report
Thermo Fisher Scientific Inc. has released its 2025 Form 10-K report, highlighting a 4% increase in total revenues to $44,556 million and a 7% rise in diluted EPS to $17.74. The report details robust performance across its four key business segments, strategic acquisitions to enhance proteomics and bioproduction capabilities, and ongoing investments in innovation and global expansion. The company also addresses challenges and risks including market competition, economic volatility, and regulatory pressures.